GSK:NYSE
GSK plc
48,00 $
arrow_downward
−1,32%(−0,64) 1D
10. sep., 12:27:23 GMT -4 · USD
search
Vsi simboli
1D
5D
1M
6M
TLDD
1L
5L
MAKS
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za GSK …
Odpri
48,47 $
Visoka
48,59 $
Nizka
47,98 $
Tržna kapitalizacija
97,51 mrd.
Povprečni promet
3,24 mio.
Promet
777,72 tis.
Dividenda
3,79 %
Četrtletna dividenda
0,45 $
Prvi trgovalni dan brez upravičenja do dividende
13. avg. 2026
Razmerje med ceno delnice in čistim dobičkom
15,02
52-tedenski najvišji tečaj
61,70 $
52-tedenski najnižji tečaj
39,29 $
Čisti dobiček na delnico
3,20 $
Beta
0,27
Št. izdanih delnic
2,02 mrd.
Št. zaposlenih
67 tis.
Odpri
48,47 $
Visoka
48,59 $
Nizka
47,98 $
Tržna kapitalizacija
97,51 mrd.
Povprečni promet
3,24 mio.
Promet
777,72 tis.
Dividenda
3,79 %
Četrtletna dividenda
0,45 $
Prvi trgovalni dan brez upravičenja do dividende
13. avg. 2026
Razmerje med ceno delnice in čistim dobičkom
15,02
52-tedenski najvišji tečaj
61,70 $
52-tedenski najnižji tečaj
39,29 $
Čisti dobiček na delnico
3,20 $
Beta
0,27
Št. izdanih delnic
2,02 mrd.
Št. zaposlenih
67 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
Zacks Investment Research
·
pred 1 uro
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
TipRanks
·
pred 1 uro
GSK Reports Executive Acquisition of Notional ADS in Savings Plan
Kalkine Media
·
pred 2 urama
Is GSK (LSE:GSK) Stock Gaining Fresh Momentum After Its Oncology Acquisition Move Today?
Traders Union
·
pred 7 urami
Will GSK stock hold GBX1,747 support as seller pressure persists?
Profil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Vizitka: GSK plc
Generalni direktorEmma Walmsley | Emma Walmsley
Št. zaposlenih66,8 tis.
Ustanovljeno27. dec. 2000
Sedež-
Sektor-
Spletno mestogsk.com